Articles related to DRUG SAFETY & INTERACTIONS

This study highlights a potential risk associated with benzodiazepine treatment in high-risk individuals. Learn more about how this could impact your practice.

Discover the emerging evidence on the cancer risks associated with commonly prescribed medications and what it means for your prescribing habits.

A recent study found that patients who used proton pump inhibitors (PPIs) for more than 4.4 years had a 33% higher risk of developing dementia during the follow-up period.

Explore a comprehensive look at gabapentin, its mechanisms, widespread uses, potential side effects, and crucial factors to consider for ensuring patient safety and treatment efficacy.

Delving into the potential risks and effects of combining linezolid with methadone, buprenorphine, and/or dextroamphetamine, this study offers crucial insights that can impact your practice. Stay updated and informed about these interactions to provide the best patient care.

Delve into the changes in the updated Beers criteria and their implications for medication use in older patients. The American Geriatrics Society (AGS) has recently revised the Beers criteria. Significantly, these guidelines advise physicians to be cautious when prescribing medications like warfarin and sodium-glucose cotransporter-2 (SGLT2) inhibitors for patients over 65. Importantly, warfarin is now a drug to avoid in initial therapy for venous thromboembolism or nonvalvular atrial fibrillation unless alternatives are contraindicated or face significant usage barriers. The Beers criteria are organized into five distinct categories. These include potentially inappropriate medications, ones that might be inappropriate for patients with certain conditions, medications requiring careful usage, potential drug-drug interactions, and medications needing renal function-based dosage adjustments. An expert panel sifted through evidence from June 1, 2017, to May 31, 2022, to create these updates. These guidelines apply to patients aged 65 years and older in most care settings in the US, excluding hospice and end-of-life care situations. Among the notable changes since 2019 is the inclusion of warfarin. For older patients using warfarin long-term, continuation might be reasonable if they show well-controlled international normalized ratios and no adverse effects. Additional drugs introduced since 2019 include ticagrelor and SGLT2 inhibitors (use […]